Treatment of Lower Respiratory Tract Infection in Patients with Multiple Antibiotic Allergies

Rationale for Antibiotic Selection

The American Academy of Otolaryngology-Head and Neck Surgery recommends a respiratory fluoroquinolone (levofloxacin or moxifloxacin) as first-line treatment for patients with lower respiratory tract infection and multiple beta-lactam and sulfa allergies 1, 2
Beta-lactams are contraindicated in patients with documented allergies to ampicillin and cephalexin, due to the risk of cross-reactivity with other cephalosporins 3
Sulfa drugs are contraindicated in patients with a sulfa allergy, eliminating trimethoprim-sulfamethoxazole as an alternative option 1, 2

Levofloxacin 750 mg orally once daily for 5 days, or moxifloxacin 400 mg orally once daily for 5 days, are recommended as first-line therapy for patients with lower respiratory tract infection and multiple antibiotic allergies 1, 2, 4
Doxycycline 100 mg orally twice daily for at least 7 days is an alternative option, with 81% calculated clinical efficacy and 80% bacteriologic efficacy 1, 2, 4
Azithromycin or clarithromycin may be considered, but have important limitations, including high resistance rates and lower efficacy 1, 2, 5, 6

The choice between outpatient oral therapy and hospitalization depends on severity markers, including respiratory rate, systolic blood pressure, and oxygen saturation 6, 5
Hospital admission is indicated for patients with severe hypoxemia, systolic blood pressure <90 mmHg, or need for mechanical ventilation 6
The duration of therapy is 5 days for fluoroquinolones, and at least 7 days for doxycycline or macrolides 1, 2, 6, 4
Clinical response should be reassessed at 48-72 hours, with expectations of improvement in fever, dyspnea, and cough 1, 5, 6

Cephalosporins with similar side chains to cephalexin should not be used in patients with a documented cephalexin allergy, due to the risk of cross-reactivity 3
Macrolides should not be used as first-line therapy, due to high resistance rates and lower efficacy 2
Combination therapy with clindamycin should not be used in patients with a documented clindamycin allergy 1, 2

Respiratory fluoroquinolones (levofloxacin 750 mg daily for 5 days or moxifloxacin 400 mg daily for 5 days) are the first‑line replacement for amoxicillin‑clavulanate in penicillin‑allergic patients – European Respiratory Society recommendation. 7
Macrolides (azithromycin or clarithromycin) should be used only with caution; resistance rates exceed 10 % in the United Kingdom and clinical efficacy is lower – European Society of Clinical Microbiology and Infectious Diseases guidance. 8, 9

Respiratory fluoroquinolones as monotherapy are recommended for hospitalized penicillin‑allergic patients with non‑severe CAP – European Respiratory Society guideline. 7

Add respiratory fluoroquinolone therapy and consider additional anti‑Pseudomonal coverage when risk factors for Pseudomonas are present – European Respiratory Society recommendation. 7
Severe CAP is defined by any of the following: systolic blood pressure < 90 mmHg, PaO₂/FiO₂ < 250, or multilobar pulmonary involvement – European Respiratory Society criteria. 7

Guidelines consistently favor respiratory fluoroquinolones or doxycycline over cephalosporins for lower respiratory infections in penicillin‑allergic patients, regardless of the type of hypersensitivity reaction. – European Respiratory Society and European Society of Clinical Microbiology and Infectious Diseases. 8, 9, 7

While respiratory fluoroquinolones remain the most effective option for penicillin‑allergic patients with lower respiratory infections, their use should be reserved to limit the development of resistance – European Society of Clinical Microbiology and Infectious Diseases position. 8